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Abstract
In a multimodal PET imaging approach, we determined the differential contri-
bution of neurofibrillary tangles (measured with [18F]AV-1451) and beta-amy-
loid burden (measured with [11C]PiB) on degree of neurodegeneration (i.e.,
glucose metabolism measured with [18F]FDG-PET) in patients with Alzheimer’s
disease. Across brain regions, we observed an interactive effect of beta-amyloid
burden and tau deposition on glucose metabolism which was most pronounced
in the parietal lobe. Elevated beta-amyloid burden was associated with a stron-
ger influence of tau accumulation on glucose metabolism. Our data provide the
first in vivo insights into the differential contribution of Ab and tau to neu-
rodegeneration in Alzheimer’s disease.
Introduction
Extracellular beta-amyloid plaques (Ab) and intracellular
neurofibrillary tangles (tau) are the primary pathological
hallmarks of Alzheimer’s disease (AD). Postmortem stud-
ies have suggested that Ab deposition is abundantly dis-
tributed in the cortex already early in the course of the
disease, whereas tau formation, synaptic loss, and gliosis
progress to advanced stages of AD.1 The temporal
dynamics of these neuropathologic processes may be one
explanation for the close correlation between tau pathol-
ogy and dementia severity, whereas Ab shows no additive
predictive value.2 Interestingly, animal studies – more
appropriate to investigate the temporal relationship of
protein accumulation than postmortem studies – recently
suggested a synergistic effect of Ab-mediated tau propaga-
tion and neuronal loss.3 However, the relative contribu-
tions of Ab and tau pathology to AD-related
neurodegeneration in humans remain elusive.
PET imaging studies have not observed a distinct regio-
nal relationship between Ab-deposition and neurodegener-
ation.4 With the advent of a novel PET tracer ([18F]AV-
1451 aka T807) that shows high affinity to intracellular tau
tangle pathology,5 it has now become possible to examine
the potential interactive relationship between protein
aggregation and neurodegeneration in vivo. Understanding
the contribution of tau and Ab pathology to neurodegener-
ation in AD will greatly advance our knowledge of disease
mechanisms and could become paramount in identifying
or evaluating therapeutic approaches.
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To this end, we assessed the relationship of tau and Ab
pathology to global and regional patterns of hypometabo-
lism in AD patients using trimodal PET (i.e., [11C]PiB
PET, [18F]AV-1451, [18F]FDG-PET) and tested the degree
to which Ab and tau deposition contribute to neurode-
generation on AD.
Methods
Participants
Participants (N = 10; MeanAge = 67.2 years, SDAge = 7.3;
MeanMMSE = 22 SDMMSE = 4) were clinically diagnosed
with typical AD in the interdisciplinary center for mem-
ory disorders of the University Hospital Cologne and the
Department of Psychiatry, University Hospital Bonn using
the recommended diagnostic guidelines,6 and supported
by the diagnostic PET imaging results evaluated by the
experts from the Department of Nuclear Medicine (J. H.,
T. v. E., A. D.). All participants underwent a trimodal
PET imaging protocol at the University Hospital Cologne,
including [11C]PiB PET, [18F]AV-1451, [18F]FDG-PET in
the course of their clinical work-up for dementia. Patients
signed an informed consent regarding the scientific evalu-
ation and possible publication of their data. The study
was performed with approval of the Ethics Committee of
the Faculty of Medicine of the University of Cologne.
PET imaging protocol and analysis
All PET scans were performed at the Department of
Nuclear Medicine, University Hospital Cologne, Germany,
with a Siemens Biograph mCT Flow 128 Edge scanner
(Siemens, Knoxville, TN).
PET imaging protocol
All PET scans were iteratively reconstructed using a 3-D
OSEM algorithm (four iterations, 12 subsets, Gaussian fil-
ter: 5 mm Full width at half maximum (FWHM),
128 9 128 matrix, slice thickness of 3 mm). PiB PET data
were acquired for 30 min, 41  15 min after injection of
305  107 MBq of [11C]For FDG PET, a ten minute
acquisition scan was performed 39 (+) 18 min after
injection of 217, 5 (+) 16 [18F]FDG-PET. Tau PET was
acquired for 15 min, 94  15 min after injection of
248  58 MBq of [18F]AV-1451.
Image analysis
All image analyses were conducted using SPM8 (Wellcome
Trust Centre for Neuroimaging). First, PiB and AV-1451
scans were coregistered to the FDG image of each patient.
Second, we spatially normalized coregistered PET scans to
an aging and dementia-specific [18F]FDG PET template.7
Standardized uptake values ratio (SUVR) images were cre-
ated by dividing each image by the nonspecific binding of
an automated anatomical labeling (AAL)-modified cerebel-
lar region, excluding the peduncles.
Creation of z-transformed deviation images
(z-maps)
To assess AD-related differences in tau deposition and
glucose hypometabolism, we computed voxel-wise mean
(l) and standard deviation (r) of SUVR values for healthy
controls. The healthy control groups were provided
by AVID Radiopharmaceuticals ([18F]AV-1451; N = 15,
AgeMean = 64.4, MMSE=29.5), from the Alzheimer’s Dis-
ease Imaging database (http://adni.loni.usc.edu; [18F]FDG
PET N = 18, AgeMean = 65.8, MMSE = 29.1*; *MMSE
scores for three healthy controls were not available
from the ADNI database), and 15 healthy controls
(AgeMean = 64.0, MMSE = 29.2) who underwent a [
11C]
PiB PET imaging protocol.8 We then computed z-score
deviations for every voxel (x) using the formula z ¼ xlr
 
.
The deviation images were overlaid on the lateral surface of
the left and the right hemisphere using to Freesurfer 5.3
(http://surfer.nmr.mgh.harvard.edu).
ROI analysis
A structure-based parcellation of cortical and hippocam-
pal areas (AAL) was used and z-scores were extracted. For
a region-specific analysis, we selected the region of
Figure 1. Spatial correspondence of mean Fluordexoglucose (FDG)
deviation and mean tau deviation but not amyloid deviation in AD
patients. AD, Alzheimer’s disease patients. Deviation images were
projected on the lateral surface of the left and the right hemisphere
using FreeSurfer.
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interests (ROIs) that fall into six cortical structures (i.e.,
frontal, temporal, parietal, occipital lobe, insular cortex/
cingulum, and hippocampus). Z-scores were averaged on
the group level for each ROI to assess the regional pattern
of FDG hypometabolism and its correspondence with
regional tau and Ab pathology.
Statistical analysis
We performed uni- and multivariate analyses to assess
the relationship of tau and Ab burden to measure hypo-
metabolism. Additionally, we examined the reliability of
the individual correlation of FDG hypometabolism with
tau and Ab deviation across patients using the Wilcoxon
signed rank test. We performed all analyses in R and Sys-
tat 13 (Systat Software, Inc., Chicago, IL) and multivariate
analyses were corrected for multiple comparisons.
Results
We observed a close spatial correspondence of the pattern
of mean FDG deviation and mean tau deviation, whereas
a widespread and diffuse pattern of amyloid was seen in
the amyloid deviation map (see Fig. 1).
Across brain regions, we observed a strong positive
relationship of mean tau deposition and hypometabolism
(r = 0.71, P < 0.001; see Fig. 2A), whereas the pattern of
Ab burden and hypometabolism was negatively related
(r = 0.41, P < 0.001; see Fig. 2B).
The multivariate analysis yielded an interactive effect of
tau deposition and Ab burden predicting measures of AD-
related hypometabolism, such that regions with higher PiB
uptake showed a stronger relationship of tau and hypome-
tabolism, compared to regions with lower Ab burden
(Tau 9 Ab t = 2.003, P = 0.04; see Table 1C, Fig. 2C).
Figure 2. (A) Significant relationship of the pattern of FDG hypometabolism and the pattern of tau deposition across brain regions in cortical and
subcortical AAL regions. (B) A positive relationship of the pattern of FDG hypometabolism and the pattern of Ab burden in cortical and
subcortical AAL regions. (C) Regression plane of the interaction of tau (y-axis) and Ab (x-axis) deposition on hypometabolism (z-axis). AAL,
automated anatomical labeling.
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In the region-specific analyses, we found significant
associations of hypometabolism and tau deposition for all
regions except insular cortex/cingulum and hippocampus
(for details, see Table 1A). Interestingly, regional Ab bur-
den was only negatively related to hypometabolism in
frontal and insular/cingulate areas (see Table 1B). The
multivariate analysis approach detected a significant main
effect of tau deposition on regional hypometabolism in all
regions. Importantly, Ab burden, when considered in the
presence of tau, did not exert an effect on regional
hypometabolism, except for the parietal lobe, where
an interactive effect was observed (see Table 1C). Finally,
the correlation indices of tau and FDG (rmean = 0.46)
across participants significantly differed from the
correlation of amyloid and FDG (rmean = 0.28)
(ZWicolxonSignedRankTest = 2.80, P =0.005). Furthermore,
the probability for a positive correlation between tau and
FDG was significant (PsignTest = 0.002).
Discussion
Here, we report the first evidence for an in vivo marker
of tau pathology as measured with [18F]AV-1451 that
relates to the pattern of neurodegeneration as measured
with [18F]FDG in a sample of clinically diagnosed cases of
AD. While the pattern of hypometabolism across brain
regions was predicted by the interactive effect of Ab and
tau, regional hypometabolism was consistently associated
with the presence of tau but not Ab, except for the pari-
etal region were an interaction was observed.
Our results are in support of accumulating evidence
derived from in vivo animal models and in vitro studies,
that neurodegenerative processes are related to an interac-
tive effect of soluble forms of Ab and hyperphosphory-
lated tau.9–11 Although current PET tracers are insensitive
to soluble oligomeric forms of Ab, studies have shown
that an increasing pathological burden of fibrillar mono-
meric Ab is associated with a higher prevalence of oligo-
meric forms.12 Therefore, it is conceivable that Ab burden
in AD, measured with in vivo PET tracers, may indirectly
relate to the toxic oligomeric forms of Ab and in concert
with tau deposition, contribute to patterns of neurode-
generation in AD.
The observed regional dissociation favoring the role of
regional tau pathology on patterns of regional hypometa-
bolism may be indicative of tau-mediated neurodegenera-
tion that occurs independent of the presence of Ab.
Although it is still under debate if neurodegeneration
underlies tau-dependent Ab toxicity or Ab-dependent tau
toxicity,13 there is convincing evidence that the amount
and distribution of tau correlates with the severity and
the duration of dementia,14 underscoring the independent
contribution of tau pathology.
Our results offer insights into the dynamic interaction
of tau pathology and amyloid burden with hypometabo-
lism in typical AD. Most regions showed a direct relation-
ship of tau pathology and hypometabolism, irrespective
of Ab. However, in the parietal region, an early site of
amyloid deposition and decreased hypometabolism in
AD, an interactive effect of Ab and tau was observed.
This result may be indicative of the joint downstream
effect of both protein pathologies in regions affected early
in the course of the disease. To further evaluate the con-
tribution of both molecular hallmarks to neurodegenera-
tion, atypical AD representations may be an optimal
population to examine the distinct spatial overlap of
pathology and hypometabolism.
The lack of a significant relationship between the pat-
tern of tau pathology and hypometabolism in the hip-
pocampus, an early site of tangles deposition in AD15 is –
at least at first sight – somewhat surprising. Consistent
with the literature,16,17 we found moderate levels of
Table 1. Result of univariate (A and B) and multivariate analysis (C)
on the relationship among tau and amyloid burden and hypometabo-
lism.
A) Tau and FDG
hypometabolism
B) Amyloid and FDG
hypometabolism
r P r P
Hippocampus 0.34 0.60 0.58 0.42
Temporal lobe 0.71 0.00 0.12 0.65
Frontal lobe 0.59 0.00 0.49 0.00
Parietal lobe 0.88 0.00 0.24 0.44
Occipital lobe 0.92 0.00 0.34 0.27
Insular cortex/cingulum 0.30 0.46 0.91 0.00
(C) Multivariate analysis
b SE b b P-value
Global hypometabolism
Tau deposition 0.15 0.25 0.33 0.53
Amyloid deposition 0.34 0.06 0.60 0.00
Tau 9 amyloid 0.07 0.03 1.0 0.04
Temporal hypometabolism
Tau deposition 0.21 0.05 0.75 0.00
Amyloid SUVR 0.05 0.09 0.11 0.56
Frontal hypometabolism
Tau deposition 0.34 0.14 0.45 0.02
Amyloid deposition 0.06 0.05 0.23 0.23
Parietal hypometabolism
Tau deposition 0.19 0.53 3.7 0.00
Amyloid deposition 0.28 0.31 0.32 0.39
Tau 9 amyloid 0.21 0.08 3.1 0.04
Occipital hypometabolism
Tau deposition 0.24 0.03 0.89 0.00
Amyloid deposition 0.18 0.09 0.21 0.08
SUVR, standardized uptake values ratio.
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hypometabolism in the hippocampus of AD patients,
while hippocampal tau deposition did not differ from
normal age-matched controls. Therefore, hippocampal tau
deposition may not be sensitive enough to distinguish
normal-aged individuals from AD patients, as tau is
present in medial temporal lobe regions in almost all
individuals over the age of 6518 and maybe representative
of primary or additive age-related tauopathy.19
Our results offer new avenues for future research: From
a spreading perspective,20 it could be argued, that tempo-
ral tau burden spreads to adjacent parietal regions, where
elevated levels of Ab accelerate the independent propaga-
tion of tau to other regions. Future approaches including
longitudinal studies may test this hypothesis.
Taken together, our data provide the first evidence of
the differential contribution of Ab and tau to patterns of
neurodegeneration in AD measured in vivo, which may
prove to be critical in the design of disease modifying
interventions.
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